United Therapeutics (UTHR) News Today $361.74 -5.62 (-1.53%) As of 02:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Hussman Strategic Advisors Inc. Purchases 2,100 Shares of United Therapeutics Co. (NASDAQ:UTHR)Hussman Strategic Advisors Inc. increased its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 33.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,400 shares of the biotechnology company's stock after aFebruary 21 at 6:37 AM | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Receives $382.08 Consensus PT from BrokeragesFebruary 21 at 1:47 AM | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) COO Sells $3,710,500.00 in StockUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at $956,195.85. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.February 20 at 5:11 PM | marketbeat.comUnited Therapeutics Corp (UTHR) to Announce Q4 and Full Year 2024 Financial ResultsFebruary 20 at 10:34 AM | gurufocus.comMichael Benkowitz Sells 10,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockFebruary 20 at 4:57 AM | insidertrades.comKestra Investment Management LLC Acquires Shares of 1,708 United Therapeutics Co. (NASDAQ:UTHR)Kestra Investment Management LLC acquired a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,708 shares of the biotechnology company's stock, valFebruary 19 at 5:15 AM | marketbeat.comRhumbline Advisers Sells 2,506 Shares of United Therapeutics Co. (NASDAQ:UTHR)Rhumbline Advisers decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 1.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 126,338 shares of the biotechnology company's stock after selling 2,506 shares during theFebruary 18 at 3:55 AM | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the thirteen brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendFebruary 18 at 2:30 AM | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Stock Holdings Trimmed by New York State Teachers Retirement SystemNew York State Teachers Retirement System lowered its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 1.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,711 sharesFebruary 17, 2025 | marketbeat.comUnited Therapeutics (UTHR) Projected to Post Quarterly Earnings on WednesdayUnited Therapeutics (NASDAQ:UTHR) will be releasing earnings before the market opens on Wednesday, February 19, Financial Modeling Prep reports.February 17, 2025 | marketbeat.comAustralianSuper Pty Ltd Has $66.96 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)AustralianSuper Pty Ltd lifted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 577.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 189,780 shares of the biotechnology comFebruary 16, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Allspring Global Investments Holdings LLCAllspring Global Investments Holdings LLC lessened its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 53.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 84,608 shares of the biotechnolFebruary 16, 2025 | marketbeat.comQ4 EPS Estimate for United Therapeutics Reduced by AnalystFebruary 15, 2025 | americanbankingnews.comLeerink Partnrs Issues Negative Estimate for UTHR EarningsUnited Therapeutics Co. (NASDAQ:UTHR - Free Report) - Leerink Partnrs reduced their Q4 2024 EPS estimates for shares of United Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now expects that the biotechnology company will earn $6.90 per share forFebruary 13, 2025 | marketbeat.comUnited Therapeutics: Growth Prospects and Financial Performance Support ‘Buy’ RatingFebruary 13, 2025 | tipranks.comWhat is Leerink Partnrs' Forecast for UTHR FY2024 Earnings?United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Equities research analysts at Leerink Partnrs cut their FY2024 earnings per share (EPS) estimates for United Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now expects that the biotechnology cFebruary 12, 2025 | marketbeat.comUnited Therapeutics Corporation (UTHR): A Cheap Biotech Stock to Invest In NowFebruary 12, 2025 | insidermonkey.comQuent Capital LLC Sells 3,232 Shares of United Therapeutics Co. (NASDAQ:UTHR)Quent Capital LLC reduced its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 76.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 983 shares of the biotechnology companFebruary 12, 2025 | marketbeat.comSumitomo Mitsui Trust Group Inc. Has $33.05 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)Sumitomo Mitsui Trust Group Inc. reduced its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 5.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 93,673 shares of the biotechnology companyFebruary 12, 2025 | marketbeat.comUnited Therapeutics' president sells shares worth $3.48 millionFebruary 11, 2025 | msn.comUnited Therapeutics Co. (NASDAQ:UTHR) COO Sells $3,480,600.00 in StockUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $348.06, for a total value of $3,480,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $896,950.62. This represents a 79.51 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.February 11, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) is Polaris Capital Management LLC's 9th Largest PositionPolaris Capital Management LLC decreased its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 7.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 131,850 shares of the biotechnology company's stock aftFebruary 11, 2025 | marketbeat.comEmpirical Finance LLC Trims Stake in United Therapeutics Co. (NASDAQ:UTHR)Empirical Finance LLC lowered its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 47.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,297 shares of the biotechnology coFebruary 11, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Empowered Funds LLCEmpowered Funds LLC lessened its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 11.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 21,532 shares of the biotechnology company's stock after selling 2,697 shares during the period. Empowered FundFebruary 11, 2025 | marketbeat.comDrugmaker to study pig kidney transplants in humans with groundbreaking trialFebruary 8, 2025 | bizjournals.comTobam Sells 19,719 Shares of United Therapeutics Co. (NASDAQ:UTHR)Tobam lowered its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 52.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,222 shares of the biotechnology company's stock afterFebruary 7, 2025 | marketbeat.comLivforsakringsbolaget Skandia Omsesidigt Has $9.90 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)Livforsakringsbolaget Skandia Omsesidigt lifted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 6,925.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 28,100 shares of the biotechnology company'sFebruary 7, 2025 | marketbeat.comLiquidia Corp.: We Have Exposure To The Upside NowFebruary 6, 2025 | seekingalpha.comUnited Therapeutics (NASDAQ:UTHR) Sees Large Volume Increase - Still a Buy?United Therapeutics (NASDAQ:UTHR) Sees Large Volume Increase - Should You Buy?February 6, 2025 | marketbeat.comState Street Corp Reduces Stake in United Therapeutics CorpFebruary 5, 2025 | gurufocus.comUnited Therapeutics president sells $3.5m in stockFebruary 5, 2025 | msn.comUnited Therapeutics price target lowered to $460 from $475 at UBSFebruary 5, 2025 | markets.businessinsider.comUnited Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz Sells 10,000 SharesUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $353.64, for a total value of $3,536,400.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $911,330.28. This represents a 79.51 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.February 4, 2025 | marketbeat.comUnited Therapeutics Says FDA Clears IND For The UKidney Xenotransplantation Clinical TrialFebruary 4, 2025 | markets.businessinsider.comUnited Therapeutics: TETON 1 study of nebulized Tyvaso for IPF fully enrolledFebruary 4, 2025 | markets.businessinsider.comUnited Therapeutics scores FDA go-ahead for pig organ transplant clinical trialFebruary 4, 2025 | bizjournals.comUnited Therapeutics Corporation's (NASDAQ:UTHR) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?February 4, 2025 | finance.yahoo.comChina Universal Asset Management Co. Ltd. Acquires 909 Shares of United Therapeutics Co. (NASDAQ:UTHR)China Universal Asset Management Co. Ltd. grew its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 10.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,466 shares of the biotechnologyFebruary 1, 2025 | marketbeat.comJanney Montgomery Scott LLC Acquires 789 Shares of United Therapeutics Co. (NASDAQ:UTHR)Janney Montgomery Scott LLC boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 9.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,427 shares of the biotechnoloFebruary 1, 2025 | marketbeat.comShort Interest in United Therapeutics Co. (NASDAQ:UTHR) Drops By 14.3%United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) was the target of a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 1,920,000 shares, a drop of 14.3% from the December 31st total of 2,240,000 shares. Approximately 4.4% of the company's stock are sold short. Based on an average daily volume of 317,200 shares, the days-to-cover ratio is presently 6.1 days.January 31, 2025 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) Stock Price Down 4.9% - Time to Sell?United Therapeutics (NASDAQ:UTHR) Trading Down 4.9% - Time to Sell?January 30, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by New England Research & Management Inc.New England Research & Management Inc. cut its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 26.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,640 shares of the biotechnology company's stJanuary 30, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Bought by Milestone Asset Management LLCMilestone Asset Management LLC grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 56.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 2,874 shares of the biotechnology company's stock after purchasing an adJanuary 30, 2025 | marketbeat.comRobeco Institutional Asset Management B.V. Has $67.72 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)Robeco Institutional Asset Management B.V. trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 2.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 191,925 shares of the bioJanuary 30, 2025 | marketbeat.comSwedbank AB Has $118.38 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)Swedbank AB cut its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 19.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 335,505 shares of the biotechnology company's stock after selling 79,432 shJanuary 29, 2025 | marketbeat.comUnited Therapeutics president sells shares worth $3.7 millionJanuary 28, 2025 | msn.comUnited Therapeutics Co. (NASDAQ:UTHR) COO Sells $3,707,100.00 in StockUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $370.71, for a total transaction of $3,707,100.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at $955,319.67. This represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.January 28, 2025 | marketbeat.comKBC Group NV Purchases 7,169 Shares of United Therapeutics Co. (NASDAQ:UTHR)KBC Group NV increased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 6.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 123,055 shares of the biotechnology company's stock after purchasing an additional 7,169 shares duJanuary 28, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by SG Americas Securities LLCSG Americas Securities LLC lifted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 117.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,244 shares of the biotechnology companyJanuary 28, 2025 | marketbeat.comPacer Advisors Inc. Buys 30,931 Shares of United Therapeutics Co. (NASDAQ:UTHR)Pacer Advisors Inc. lifted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 5.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 597,634 shares of the biotechnology company's stock after acquirinJanuary 27, 2025 | marketbeat.com Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address UTHR Media Mentions By Week UTHR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UTHR News Sentiment▼0.820.60▲Average Medical News Sentiment UTHR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UTHR Articles This Week▼1411▲UTHR Articles Average Week Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALNY News BIIB News INCY News BMRN News NBIX News EXEL News EXAS News RGEN News HALO News MDGL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:UTHR) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
